Moreover, although BCMA is expressed on most of malignant plasma cells and is recognized as a validated target in multiple myeloma therapy, its expression levels are heterogeneous, resulting in variable responses in patients with multiple myeloma (5, 58). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.